It looks like you're using an ad blocker.

To enjoy our content, please include The Japan Times on your ad-blocker's list of approved sites.

Thank you for supporting our journalism.

  • HOME DELIVERY |
  • SUBSCRIBE |
  • Login
  • My Account
TODAY'S PRINT EDITION

The Japan Times The Japan Times

medicine

  • Login
  • SUBSCRIBE
  • My Account
  • HOME DELIVERY ≫
  • (FREE ARTICLE)
  • MENU
  • Search
  • News
  • Opinion
  • Life
  • Community
  • Culture
  • Sports
  • City Guide
  • Support
  • Search
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
We need to know why the omicron BA.5 wave is ebbing

Commentary / World Aug 12, 2022

We need to know why the omicron BA.5 wave is ebbing

by Faye Flam

Scientists are starting to figure out why infection rates rise and fall. But a collapse in COVID-19 testing will make it much harder to predict the next surge.

Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

Business / Corporate Aug 9, 2022

Pfizer to buy Global Blood Therapeutics in $5.4 billion deal

Pfizer will gain Oxbryta, South San Francisco-based Global Blood’s therapy for sickle-cell disease that sold about $195 million last year.

Japan to roll out COVID vaccine that targets omicron as early as October

National Aug 6, 2022

Japan to roll out COVID vaccine that targets omicron as early as October

The new vaccine is under development and was found to increase neutralizing antibodies against the BA.1 subvariant and were also effective for the BA.5 subtype to some extent.

Japan to let prefectures declare new anti-COVID measures but won't curb social activities

National Jul 29, 2022

Japan to let prefectures declare new anti-COVID measures but won't curb social activities

by Tomoko Otake

Governors will now be able to declare that their prefectures are in need of measures to counter the BA.5 subvariant when their health care systems are severely strained.

Everything you need to know about BA.5, the dominant strain spreading across Japan

National / Science & Health | EXPLAINER Jul 28, 2022

Everything you need to know about BA.5, the dominant strain spreading across Japan

by Tomoko Otake

Amid a seventh wave of infections, daily case numbers have been reaching unprecedented highs, with the nation logging 969,000 cases over the seven-day span to Sunday.

Siga and peers rise on optimism over therapies to treat monkeypox

World / Science & Health Jul 26, 2022

Siga and peers rise on optimism over therapies to treat monkeypox

by Bre Bradham

It has been a bumpy few months for shares of firms tied to the outbreak, as investors have piled in only to rush out on uncertainty about what medicine could be needed.

Three Japan-approved drugs may be effective against omicron BA.5

National / Science & Health Jul 21, 2022

Three Japan-approved drugs may be effective against omicron BA.5

A team found that small-molecule antiviral drugs nirmatrelvir, molnupiravir and remdesivir curbed virus activity in cultured monkey cells infected with BA.5.

Health ministry panel delays decision on emergency approval for Shionogi’s COVID pill

National / Science & Health Jul 20, 2022

Health ministry panel delays decision on emergency approval for Shionogi’s COVID pill

by Tomoko Otake

The delay is a blow to one of Japan's largest drugmakers and also raises questions about the process for drugs to gain fast-track approvals in times of emergency.

Haven’t had COVID-19 yet? Maybe you’ve just been lucky

Commentary / World Jul 14, 2022

Haven’t had COVID-19 yet? Maybe you’ve just been lucky

by Faye Flam

With highly contagious new variants in circulation, anyone who hasn’t yet gotten sick can probably thank randomness or genetics more than behavior.

Japanese panel postpones verdict on Shionogi’s COVID pill until July

National / Science & Health Jun 23, 2022

Japanese panel postpones verdict on Shionogi’s COVID pill until July

by Tomoko Otake

The panel “could not reach a conclusion,” as its members were divided over several points including the efficacy of the drug, according to a health ministry official.

As Japan's verdict on Shionogi's COVID pill nears, questions persist over efficacy

National Jun 21, 2022

As Japan's verdict on Shionogi's COVID pill nears, questions persist over efficacy

by Tomoko Otake

There have been calls for Japan to acquire more weapons against COVID-19, especially domestically produced ones, but medical experts are unsure of the drug's merits.

U.S. monkeypox response repeats COVID-19 mistakes

Commentary / World Jun 21, 2022

U.S. monkeypox response repeats COVID-19 mistakes

by Richard Danzig and James Lawler

Health officials, with the monkeypox outbreak, are again failing to understand that a new epidemic may not take the same course as the last one.

« 1 … 13 14 15 … 46 »
  • WHAT’S TRENDING
  • EDITORS’ PICKS
  • Nadeshiko Japan downs Costa Rica to move into knockout stage

    Thumbnail image
  • AI is rewriting the rules of $200 billion games industry

    Thumbnail image
  • Indonesia rides EV rush to domestic IPO boom

    Thumbnail image
  • 'Japan's Anatolia' becomes a home away from home for Kurds and Turks

    Thumbnail image
  • From 'Young General' to 'Supreme Leader': The evolution of Kim Jong Un

    Thumbnail image

PODCAST

  • DEEP DIVE

    A tale of two Fujis: Bullet climbs, crowds and Lizzo

Return to The Japan Times top page
JT Digital Archives The Japan Times Alpha JT Bookclub The Japan Times Jobs Education in Japan
  • SUBSCRIBE
  • NEWSLETTERS
  • ePaper Edition
  • News
    • National
    • World
    • Business
    • Asia Pacific
    • Reference
    • Columns
    • Multimedia
  • Opinion
    • Editorials
    • Commentary
    • Cartoons
  • Life
    • Travel
    • Digital
    • Food & Drink
    • Environment
    • Style & Design
    • Language
    • Lifestyle
    • People
    • Columns
    • Multimedia
  • Community
    • Voices
    • Issues
    • Our Lives
    • Event listings
    • How-tos
    • Columns
  • Culture
    • Film
    • Music
    • Art
    • Stage
    • Events
    • Festivals
    • Books
    • TV
    • Columns
    • Multimedia
  • Sports
    • Rugby
    • Baseball
    • Soccer
    • Basketball
    • Sumo
    • Figure Skating
    • Tennis
    • More Sports
    • Columns
    • Multimedia
  • City Guide
    • Restaurants
    • Places
  • Support
    • About us
    • Faqs
  • About us
  • Contact us
  • Work with us
  • Privacy Policy
  • Link policy
  • Republishing
  • FAQs
  • Announcements
  • Press
  • Sitemap
  • Advertise

The Japan Times LTD. All rights reserved.

The Japan Times